Ardevora Asset Management LLP Decreases Holdings in Thermo Fisher Scientific (TMO)

Ardevora Asset Management LLP reduced its position in shares of Thermo Fisher Scientific (NYSE:TMO) by 1.5% in the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 157,400 shares of the medical research company’s stock after selling 2,400 shares during the quarter. Ardevora Asset Management LLP’s holdings in Thermo Fisher Scientific were worth $32,497,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of TMO. Icon Wealth Partners LLC bought a new stake in shares of Thermo Fisher Scientific during the 4th quarter worth $105,000. Keeler Thomas Management LLC bought a new stake in shares of Thermo Fisher Scientific during the 4th quarter worth $106,000. Virtue Capital Management LLC bought a new stake in shares of Thermo Fisher Scientific during the 4th quarter worth $127,000. Johnson Financial Group Inc. boosted its stake in shares of Thermo Fisher Scientific by 2,608.7% during the 1st quarter. Johnson Financial Group Inc. now owns 623 shares of the medical research company’s stock worth $129,000 after acquiring an additional 600 shares in the last quarter. Finally, Premia Global Advisors LLC bought a new stake in shares of Thermo Fisher Scientific during the 4th quarter worth $131,000. 86.52% of the stock is owned by hedge funds and other institutional investors.

TMO opened at $211.01 on Friday. The firm has a market capitalization of $84.12 billion, a PE ratio of 22.23, a price-to-earnings-growth ratio of 1.53 and a beta of 1.14. Thermo Fisher Scientific has a 12-month low of $209.10 and a 12-month high of $211.31. The company has a quick ratio of 0.95, a current ratio of 1.36 and a debt-to-equity ratio of 0.69.

Thermo Fisher Scientific (NYSE:TMO) last released its earnings results on Wednesday, April 25th. The medical research company reported $2.50 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $2.42 by $0.08. The company had revenue of $5.85 billion during the quarter, compared to analyst estimates of $5.62 billion. Thermo Fisher Scientific had a return on equity of 16.09% and a net margin of 10.24%. The company’s revenue for the quarter was up 22.8% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.08 earnings per share. sell-side analysts anticipate that Thermo Fisher Scientific will post 10.9 EPS for the current fiscal year.

In related news, Director William G. Parrett sold 1,000 shares of the stock in a transaction on Friday, February 23rd. The stock was sold at an average price of $211.43, for a total transaction of $211,430.00. Following the completion of the sale, the director now directly owns 11,660 shares in the company, valued at $2,465,273.80. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CEO Marc N. Casper sold 40,000 shares of the stock in a transaction on Thursday, March 22nd. The stock was sold at an average price of $210.16, for a total value of $8,406,400.00. Following the sale, the chief executive officer now owns 334,622 shares of the company’s stock, valued at $70,324,159.52. The disclosure for this sale can be found here. Insiders sold 43,500 shares of company stock valued at $9,129,330 in the last 90 days. Corporate insiders own 0.49% of the company’s stock.

Several equities research analysts have recently weighed in on the company. Zacks Investment Research lowered Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a research note on Monday, March 26th. Morgan Stanley raised their price objective on Thermo Fisher Scientific from $223.00 to $227.00 and gave the stock an “overweight” rating in a research note on Thursday, February 1st. Barclays raised their price objective on Thermo Fisher Scientific from $225.00 to $245.00 and gave the stock an “overweight” rating in a research note on Thursday, February 1st. ValuEngine raised Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research note on Friday, February 2nd. Finally, Bank of America raised their price objective on Thermo Fisher Scientific from $235.00 to $250.00 and gave the stock a “buy” rating in a research note on Thursday, February 1st. One investment analyst has rated the stock with a hold rating and seventeen have issued a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average target price of $222.21.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides analytical instruments, equipment, reagents and consumables, software, and services for research, manufacturing, analysis, discovery, and diagnostics under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific (NYSE:TMO).

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.




Leave a Reply